SCHEMBL24253827

SCHEMBL24253827

O=C1CCCC2(CCN(c3nccc(N4CC5(CC5)C4)n3)CC2)N1c1ccc(Cl)c(F)c1

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.33
EIF2AK4 Q9P2K8 2/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
KCNH2 Q12809 1/20 0.32
LTC4S Q16873 1/20 0.32
ACACB O00763 1/20 0.31
CCR4 P51679 7/20 0.31
CACNA1H O95180 1/20 0.31
SUV39H2 Q9H5I1 1/20 0.31
CYP11B2 P19099 1/20 0.30
CDK4 P11802 1/20 0.30
CCND1 P24385 1/20 0.30
CCND3 P30281 1/20 0.30
CDK6 Q00534 1/20 0.30
RAD51 Q06609 1/20 0.30
PDE4B Q07343 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30424094 1.00 AOC3 (0.33) AOC3EIF2AK4HCRTR1HCRTR2KCNH2
SCHEMBL24253828 0.96 HCRTR1 (0.33) AOC3EIF2AK4HCRTR1HCRTR2KCNH2
SCHEMBL30423960 0.96 HCRTR1 (0.33) AOC3EIF2AK4HCRTR1HCRTR2KCNH2
SCHEMBL30423990 0.89 CYP11B2 (0.35) AOC3EIF2AK4HCRTR1HCRTR2KCNH2
SCHEMBL30423539 0.84 KMT2A (0.41) AOC3HCRTR1HCRTR2
SCHEMBL24253712 0.84 KMT2A (0.41) AOC3HCRTR1HCRTR2
SCHEMBL24253726 0.82 DPP4 (0.36) AOC3HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL30423561 0.82 DPP4 (0.36) AOC3HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL24253933 0.81 HCRTR1 (0.32) HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL30423566 0.81 HCRTR1 (0.32) HCRTR1HCRTR2KCNH2LTC4S

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 AOC3 3531/4885EIF2AK4 1798/4885HCRTR1 2245/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 AOC3 3531/4885EIF2AK4 1798/4885HCRTR1 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.